...
【24h】

Regaining venous access for implantation of a new lead

机译:恢复静脉通路以植入新导线

获取原文

摘要

Introduction : Venous occlusion is a relatively common complication of endocardial lead implantation. It may cause a critical problem when implantation of a new lead is needed. Traditional methods result in leaving abandoned leads. The optimal approach seems to be the extraction of the damaged or abandoned lead, regaining venous access and implantation of a new lead. Aim: To assess the efficacy and safety of new lead implantation by the method of lead extraction. Material and methods: All transvenous lead extraction procedures (203 patients) between 1 August 2008 and 15 October 2012 were assessed. The analysis included cases with leads implanted for at least 6 months prior to extraction. Results: Regaining venous access was the main indication for lead extraction in 5 patients (4.9%). The reason for new lead implantation was lead damage (n = 7) and system up-grade to cardiac resynchronization therapy (CRT) (n = 3). In total, 23 leads were extracted (9 defibrillation leads, 12 pacing leads and 2 left ventricular leads). The mean time from the implantation was 92.2 ±43.2 (48-152) months. In all cases Cook mechanical sheaths were applied. The use of the Evolution system was necessary to extract 3 leads. In all cases the new leads were successfully implanted as planned. No serious complications occurred. Conclusions : Diagnosis of venous occlusion should not be a contraindication for ipsilateral implantation of the new lead, because the techniques of transvenous lead extraction enable successful regaining of venous access.
机译:简介:静脉阻塞是心内膜植入术的一种相对常见的并发症。当需要植入新导线时,可能会导致严重问题。传统方法导致留下废弃的线索。最佳方法似乎是提取受损或遗弃的铅,恢复静脉通路和植入新铅。目的:通过铅提取方法评估新铅植入的有效性和安全性。材料和方法:评估了2008年8月1日至2012年10月15日之间的所有静脉铅提取程序(203例)。分析包括在提取前至少6个月植入铅的病例。结果:5例患者(4.9%)恢复静脉通路是铅提取的主要指征。植入新导线的原因是导线损坏(n = 7)和系统升级为心脏再同步治疗(CRT)(n = 3)。总共提取了23条导线(9条除颤导线,12条起搏导线和2条左心室导线)。植入的平均时间为92.2±43.2(48-152)个月。在所有情况下都使用库克机械护套。必须使用Evolution系统提取3条线索。在所有情况下,新导线均按计划成功植入。没有发生严重的并发症。结论:静脉阻塞的诊断不应成为新导线同侧植入的禁忌证,因为经静脉导线提取的技术可成功恢复静脉通路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号